--- title: "OSR Health (OSRH) news: delisting and convertible notes" url: "https://aibio.space/companies/osr-health/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OSRH delisting, convertible notes, Nasdaq notice and merger news: Nasdaq panel delists OSR Health over $1.00 bid price rule. OSR Health, Inc." --- OSRH OSR Health, Inc. OTC · United States # OSR Health (OSRH) news OSRH delisting, convertible notes and Nasdaq notice news Listings · 2026-10-28 ## [Nasdaq panel delists OSR Health over $1.00 bid price rule](https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/) OSR Health, whose shares have traded over the counter since Nasdaq suspended them on August 26, 2026, says it will update shareholders by November 6, 2026 on how it plans to regain a listing. ## Latest OSR Health news 1. 2026-10-15 Debt Financing [OSR Health amends VXM01 license to allow up to $15,000,000 in convertible notes](https://aibio.space/news/osr-health-amends-vxm01-license-allow-up-15-000-000-convertible-notes/) Under an amended license with BCM Europe AG, OSR Health can elect to take up to $15,000,000 of convertible notes in place of an equity purchase option. 2. 2026-09-30 Company Updates [OSR Health chief scientific officer resigns, effective immediately](https://aibio.space/news/osr-health-chief-scientific-officer-resigns-effective-immediately/) Dr. Constance Hoefer gave notice on September 30, 2026, and her resignation took effect at once, the company reported in an 8-K filed October 2. 3. 2026-08-27 Listings [OSR Health hearing before Nasdaq Panel set for September 29](https://aibio.space/news/osr-health-hearing-before-nasdaq-panel-set-september-29/) The Nasdaq Hearings Panel scheduled OSR Health's hearing for September 29, 2026, while trading in its securities remains suspended under the company's own filing. 4. 2026-08-19 Listings [OSR Health receives Nasdaq delisting determination, will request hearing](https://aibio.space/news/osr-health-receives-nasdaq-delisting-determination-will-request/) Nasdaq staff said OSR Health did not regain compliance with the $1.00 minimum bid price, and trading in its common stock and warrants will be suspended on August 26, 2026. 5. 2026-08-07 Company Updates [OSR Health says Nasdaq did not endorse its loyalty CVR program](https://aibio.space/news/osr-health-says-nasdaq-did-not-endorse-loyalty-cvr-program/) The company said a July 31 statement should not be read as Nasdaq approval of the Shareholder Loyalty CVR Program, and the August 14, 2026 record date is unchanged. 6. 2026-07-31 Company Updates [Nasdaq tells OSR Health its loyalty CVR program will not adjust price](https://aibio.space/news/nasdaq-tells-osr-health-loyalty-cvr-program-will-not-adjust-price/) In a verbal communication, Nasdaq said the Shareholder Loyalty CVR program will not trigger a mechanical price adjustment, OSR Health said on July 31, 2026. 7. 2026-06-05 Company Updates [OSR Health postpones 2026 annual meeting, no new date set](https://aibio.space/news/osr-health-postpones-2026-annual-meeting-no-new-date-set/) The board postponed the annual stockholder meeting that had been scheduled for June 18, 2026, and said it has not yet set a new date. 8. 2026-05-27 Company Updates [OSR Health agrees to buy VXM01 assets from Vaximm for $30,000,000](https://aibio.space/news/osr-health-agrees-buy-vxm01-assets-vaximm-30-000-000/) The $30,000,000 price is due in full on completion of a Phase 2 study of VXM01, and the company may make voluntary partial payments before then. 9. 2026-04-29 Company Updates [OSR Health licenses VXM01 to BCM Europe for up to $815 million](https://aibio.space/news/osr-health-licenses-vxm01-bcm-europe-up-815-million/) BCM Europe, the company's largest shareholder, holds an exclusive global license and has pledged its entire stake as collateral for milestone payments of up to $815 million. 10. 2025-09-09 Listings [OSR Holdings (now OSR Health) gets Nasdaq notice after 30 days below $1.00](https://aibio.space/news/osr-holdings-now-osr-health-gets-nasdaq-notice-after-30-days-below-1/) The company has until March 4, 2026 to regain compliance with the minimum bid price rule. Its shares keep trading on The Nasdaq Capital Market for now. 11. 2025-05-15 Distress [OSR Holdings (now OSR Health) delays quarterly report, expects $11.4 million loss](https://aibio.space/news/osr-holdings-now-osr-health-delays-quarterly-report-expects-11-4/) The company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination. 12. 2024-10-28 Mergers [Bellevue Life Sciences Acquisition (now OSR Health) lends $300,000 to OSR Holdings](https://aibio.space/news/bellevue-life-sciences-acquisition-now-osr-health-lends-300-000-osr/) Bellevue's note to its merger partner bears interest at 3.96% a year and is due on October 25, 2025. Bellevue's chief executive is also chairman of OSR Holdings. ## OSR Health at a glance - **Ticker**: OSRH - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $1.5 million ### Related companies - [IGC Pharma](https://aibio.space/companies/igc-pharma/) AMEX: IGC - [BioCardia](https://aibio.space/companies/biocardia/) NASDAQ: BCDA - [SQZ Biotechnologies](https://aibio.space/companies/sqz-biotechnologies/) OTC: SQZB - [Evofem Biosciences](https://aibio.space/companies/evofem-biosciences/) OTC: EVFM - [Zenas BioPharma](https://aibio.space/companies/zenas-biopharma/) NASDAQ: ZBIO - [Cadrenal Therapeutics](https://aibio.space/companies/cadrenal-therapeutics/) NASDAQ: CVKD - [Sana Biotechnology](https://aibio.space/companies/sana-biotechnology/) NASDAQ: SANA - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL ### Also on OTC - [Global Innovative Platforms](https://aibio.space/companies/global-innovative-platforms/) GIPL - [Panbela Therapeutics](https://aibio.space/companies/panbela-therapeutics/) PBLA - [PANACEA LIFE SCIENCES HOLDINGS, INC.](https://aibio.space/companies/panacea-life-sciences/) PLSH - [BIOFORCE NANOSCIENCES HOLDINGS, INC.](https://aibio.space/companies/bioforce-nanosciences/) BFNH - [First Choice Healthcare Solutions](https://aibio.space/companies/first-choice-healthcare-solutions/) FCHS - [International Stem Cell CORP](https://aibio.space/companies/international-stem-cell/) ISCO ## What OSR Health does OSR Health, Inc. describes itself as a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States. It says it identifies, leads and supports subsidiaries built around pharmaceutical or medical device technologies, and it expects to attract industry partners as co-investors or through technology licensing deals. Its subsidiaries are engaged in distinct areas of therapeutics research, including oral T-cell immunotherapies and recombinant biologics. The subsidiary Vaximm is developing oral T-cell immunotherapies for disorders that require the targeted elimination of specific cell populations, such as neoplasms, other proliferative diseases and chronic infections. A second subsidiary is developing a design-augmented recombinant biologic for bone and cartilage regeneration. A third subsidiary works in neurovascular surgical devices. The company says its subsidiaries hold 10 patent families of issued patents and pending applications, with anticipated expiration between 2032 to 2041. | Product or program | What it is | Stage | |---|---|---| | VXM01 DNA vaccine | DNA vaccine for use in pancreatic cancer patients, Vaximm patent family | | | VXM04-MSLN | MSLN targeting DNA vaccine for cancer immunotherapy, Vaximm patent family | | | Darnatein | Designer ligands of the TGF-beta superfamily under exclusive license | | Summarised from the company's [10-K filed Mar 31, 2026](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/ea0283154-10k_osrhold.htm). ## OSR Health annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$2.9 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | [$3.5 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | | Research and development | [$318,446](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | [$161,155](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | | Net income (loss) | | [-$2.4 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390025034116/) | | Cash from operations | [-$4.3 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | [-$1.8 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | | Cash and equivalents | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1840425/000121390026089904/) | [$341,543](https://www.sec.gov/Archives/edgar/data/1840425/000121390026037395/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.5 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about OSR Health Was OSR Health delisted? Our latest story on this, dated Oct 28, 2026: "Nasdaq panel delists OSR Health over $1.00 bid price rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nasdaq-panel-delists-osr-health-1-00-bid-price-rule/). Has OSR Health sold convertible notes? Our latest story on this, dated Oct 15, 2026: "OSR Health amends VXM01 license to allow up to $15,000,000 in convertible notes". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/osr-health-amends-vxm01-license-allow-up-15-000-000-convertible-notes/). Has OSR Health received a Nasdaq deficiency notice? Our latest story on this, dated Sep 9, 2025: "OSR Holdings (now OSR Health) gets Nasdaq notice after 30 days below $1.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/osr-holdings-now-osr-health-gets-nasdaq-notice-after-30-days-below-1/). Is OSR Health involved in a merger or acquisition? Our latest story on this, dated May 27, 2026: "OSR Health agrees to buy VXM01 assets from Vaximm for $30,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/osr-health-agrees-buy-vxm01-assets-vaximm-30-000-000/). What is the ticker symbol of OSR Health? OSR Health, Inc. trades under the ticker OSRH on OTC. Where is OSR Health listed? OSR Health, Inc. is listed on OTC. What is the SEC CIK of OSR Health? The SEC Central Index Key (CIK) for OSR Health, Inc. is 1840425. Its filings are on SEC EDGAR. How many shares does OSR Health have outstanding? 35,118,692 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is OSR Health listed under? Our directory records OSR Health, Inc. under United States. What does OSR Health do? Our directory classifies OSR Health, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of OSR Health? The ISIN recorded for OSR Health, Inc. is US68840D1028. Does aibio.space cover OSR Health? aibio.space lists OSR Health, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is OSR Health incorporated? SEC records list its state or country of incorporation as DE. What does OSR Health develop? OSR Health, Inc. describes itself as a global healthcare holding company with operations in South Korea and Switzerland and an office in the United States. It says it identifies, leads and supports subsidiaries built around pharmaceutical or medical device technologies, and it expects to attract industry partners as co-investors or through technology licensing deals. What is VXM01 DNA vaccine from OSR Health? VXM01 DNA vaccine: DNA vaccine for use in pancreatic cancer patients, Vaximm patent family Stage: Not stated in text. ## Investor discussion: OSR Health Members talk about OSR Health (OSRH). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at OSR Health, newest first. Each line links the filing it comes from. 1. 2026-10-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026113126/ea030992901ex99-1.htm) 2. 2026-10-16 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026110051/ea0308725-8k_osrhealth.htm) 3. 2026-08-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026093379/ea0303318-8k_osrhealth.htm) 4. 2026-08-19 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026091756/ea030278201ex99-1.htm) 5. 2026-03-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026025428/ea0280743-8k_osr.htm) 6. 2026-01-27 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390026007987/ea027423001ex99-1_osrhold.htm) 7. 2025-10-16 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025099393/ea026147201ex99-1_osrhold.htm) 8. 2025-09-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025086209/ea0256727-8k_osrholdings.htm) 9. 2025-05-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025044399/ea0242429-nt10q_osr.htm) 10. 2025-05-12 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025042018/ea0241726-8k_osrhold.htm) 11. 2025-04-22 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025034116/ea0237686-10k_osrhold.htm) 12. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025027038/ea0236618-nt10k_osr.htm) 13. 2025-02-28 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1840425/000121390025018204/ea0232474-8k_osrhold.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:OSRH on TradingView](https://www.tradingview.com/symbols/OTC-OSRH/). ## SEC filings and registration - **SEC name**: OSR Health, Inc. - **CIK**: 1840425 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: OSRH (OTC), OSRHW (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 10900 NE 4TH STREET, SUITE 2300, BELLEVUE, WA, 98004 - **Phone**: 425-635-7700 - **Shares outstanding**: 35,118,692 as of 2026-08-10 (10-Q filed 2026-08-14) - **Former names**: OSR Holdings, Inc.; Bellevue Life Sciences Acquisition Corp. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026110051/ea0308725-8k_osrhealth.htm) filed 2026-10-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026106429/ea0307502-8k_osrhealth.htm) filed 2026-10-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026094654/ea0303794-8k_osrhealth.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026093379/ea0303318-8k_osrhealth.htm) filed 2026-08-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026091756/ea0302782-8k_osrhealth.htm) filed 2026-08-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1840425/000121390026089904/ea0301514-10q_osrhealth.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026087087/ea0301344-8k_osrhealth.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1840425/000121390026086599/ea0301114-8k_osrhealth.htm) filed 2026-08-07 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001840425), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details OSR Health, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker OSRH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: OSR Health, Inc. - **Ticker**: OSRH - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US68840D1028 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-OSRH/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/osr-health/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "OSR Health (OSRH) news: delisting and convertible notes", 2026-10-31, https://aibio.space/companies/osr-health/